DPYSL2 (Ab-522) Antibody

What is DPYSL2 (Ab-522) antibody and what epitope does it specifically recognize?

DPYSL2 (Ab-522) antibody is a polyclonal antibody that specifically recognizes the phosphorylated form of CRMP-2 (Collapsin Response Mediator Protein-2) at serine 522 (pSer522). This antibody detects endogenous levels of CRMP-2 protein only when phosphorylated at the S522 position, making it valuable for studying site-specific phosphorylation events . The antibody is typically generated by immunizing rabbits with a synthesized phospho-peptide derived from human CRMP-2 around the phosphorylation site of S522 .

What are the recommended applications for DPYSL2 (Ab-522) antibody?

The primary validated applications for DPYSL2 (Ab-522) antibody include:

• Western Blotting (WB): Typically at dilutions of 1:500-1:3000

• ELISA: Typically at dilutions up to 1:10000

• Immunohistochemistry (IHC): For tissue section analysis

Some antibodies may also be validated for additional applications such as immunofluorescence, depending on the specific product and manufacturer .

What are the optimal conditions for using DPYSL2 (Ab-522) antibody in Western blotting?

For optimal Western blotting results with DPYSL2 (Ab-522) antibody:

• Sample preparation: Use RIPA buffer containing protease and phosphatase inhibitors to preserve phosphorylation status

• Protein loading: 20-100 μg of total protein is typically sufficient

• Gel percentage: 10% SDS-PAGE gel is recommended for optimal separation

• Transfer: PVDF membranes are commonly used for phospho-epitopes

• Blocking: 5% skim milk or BSA in TBS-T (BSA is preferred for phospho-specific antibodies)

• Primary antibody dilution: 1:500-1:2000 is typically effective

• Incubation: Overnight at 4°C yields the best results

• Detection: ECL-based systems provide sufficient sensitivity

The expected molecular weight of DPYSL2/CRMP-2 is approximately 62-64 kDa .

How should phosphatase inhibitors be incorporated when working with pSer522 DPYSL2 antibody?

When studying phosphorylated DPYSL2/CRMP-2, proper phosphatase inhibition is critical:

• Include both serine/threonine and tyrosine phosphatase inhibitors in your lysis buffer

• Recommended components include:

  • Sodium fluoride (50 mM) for serine/threonine phosphatases

  • Sodium orthovanadate (1 mM) for tyrosine phosphatases

  • β-glycerophosphate (10 mM) for acid phosphatases

  • EDTA/EGTA (5 mM) for metal-dependent phosphatases

• Prepare fresh inhibitors immediately before use

• Maintain samples at 4°C throughout processing

• Process samples quickly to minimize dephosphorylation

Failure to properly inhibit phosphatases will result in dephosphorylation and loss of signal when using phospho-specific antibodies like DPYSL2 (Ab-522) .

How can I validate the specificity of DPYSL2 (Ab-522) antibody in my experimental system?

To validate the specificity of DPYSL2 (Ab-522) antibody:

• Phosphatase treatment control: Treat half of your sample with lambda phosphatase to remove phosphorylation and confirm loss of signal

• Competitive blocking: Pre-incubate antibody with phospho-peptide used as immunogen to block specific binding

• siRNA knockdown: Use siRNA to knockdown DPYSL2/CRMP-2 expression and confirm reduction in signal

• Overexpression controls: Compare cells overexpressing wild-type CRMP-2 versus S522A mutant CRMP-2 (non-phosphorylatable)

• Positive controls: Use brain tissue or neuronal cell lines treated with CDK5 activators (like p35 overexpression)

• Comparison with total CRMP-2 antibody: Run parallel blots to confirm that total protein levels can be distinguished from phosphorylation-specific signals

In published research, siRNA knockdown reduced pSer522-CRMP2 levels by approximately 90% in control cells, confirming antibody specificity .

What are the common causes of non-specific bands when using DPYSL2 (Ab-522) antibody?

When encountering non-specific bands with DPYSL2 (Ab-522) antibody:

• Cross-reactivity with other CRMP family members:

  • The CRMP family consists of five homologous proteins (CRMP1-5)

  • Sequence similarity around phosphorylation sites can cause cross-reactivity

  • Verify specificity against recombinant CRMP family proteins

• Other potential causes and solutions:

  • Insufficient blocking: Increase blocking time or switch to 5% BSA

  • Secondary antibody cross-reactivity: Test secondary alone

  • Degradation products: Use fresh samples and include protease inhibitors

  • Splice variants: DPYSL2 has multiple isoforms that may appear as separate bands

  • Differential phosphorylation: Multiple phosphorylation sites may affect mobility

  • Post-translational modifications: SUMOylation, O-GlcNAcylation can alter migration

How should I quantify and normalize DPYSL2 phosphorylation in Western blot experiments?

For accurate quantification of DPYSL2/CRMP-2 phosphorylation:

• Express results as ratio of phospho-CRMP2 to total CRMP2:

  • This accounts for variations in total protein expression

  • Especially important when comparing conditions that might alter total protein levels

• Quantification methodology:

  • Use scientific image analysis software (e.g., ImageJ)

  • Measure mean pixel intensities of protein bands

  • Subtract local background for each measurement

  • Normalize phospho-signal to total protein signal

  • Present data as integrated density values

• Controls:

  • Include loading controls (β-actin) for normalization of total protein

  • Run phosphorylation standards if available

  • Include positive and negative controls on each blot

As noted in research, "when WT-CRMP2 is overexpressed and phosphorylation is increased, there are increased quantities of both total and phospho-CRMP2. Thus, under conditions of CRMP2 overexpression, the ratio of phospho-CRMP2/total-CRMP2 may be the most accurate representation of relative CRMP2 phosphorylation" .

How can I distinguish between different phosphorylation sites on CRMP-2 when using multiple phospho-specific antibodies?

CRMP-2 contains multiple phosphorylation sites including Ser522, Thr509, Thr514, and Thr555. To distinguish between these sites:

• Use a panel of site-specific antibodies as shown in this reference antibody panel:

• Additional techniques for phosphorylation site discrimination:

  • Use phospho-mutant constructs (S522A, T514A, etc.) as negative controls

  • Perform lambda phosphatase treatments followed by site-specific antibody detection

  • Employ phosphatase inhibitor profiles specific to different kinase pathways

  • Use higher resolution gel systems that can separate mobility shifts caused by different phosphorylation patterns

  • Consider 2D gel electrophoresis to separate phosphorylation variants by charge and mass

How can DPYSL2 (Ab-522) antibody be used to study the sequential phosphorylation events of CRMP-2?

CRMP-2 phosphorylation involves a sequential process where CDK5 phosphorylates Ser522, priming it for subsequent phosphorylation by GSK3β at Thr514 and other sites. To study this cascade:

• Time-course experiments:

  • Activate CDK5 (via p35 overexpression) and monitor pSer522 followed by other phosphorylation sites

  • Use specific kinase inhibitors at different time points

• Kinase manipulation strategies:

  • Overexpress constitutively active or dominant-negative forms of CDK5 and GSK3β

  • Use site-specific mutants (S522A) to block the priming step

  • Apply specific inhibitors of CDK5 (e.g., roscovitine) or GSK3β (e.g., lithium, SB216763)

• Co-immunoprecipitation approaches:

  • Use pSer522 antibody to immunoprecipitate followed by probing with antibodies against other phosphorylation sites

  • Investigate the temporal sequence of multiple phosphorylation events

Research has shown that "Cdk5 first phosphorylates CRMP2 at Ser522, priming it for glycogen synthase kinase 3β (GSK3β) to phosphorylate it at Thr514 and Ser518" , making this antibody critical for studying the initiation of the phosphorylation cascade.

What experimental approaches can be used to study the relationship between CRMP-2 phosphorylation at Ser522 and neurological disorders?

To investigate the role of CRMP-2 Ser522 phosphorylation in neurological disorders:

• Postmortem tissue analysis:

  • Compare pSer522-CRMP2 levels in brain tissues from patients with neurological disorders versus controls

  • Correlate with pathological markers and clinical data

  • Examine region-specific changes in phosphorylation patterns

• Animal models:

  • Analyze pSer522-CRMP2 in transgenic mouse models of neurodegenerative diseases

  • Study animal models of HIV-associated neurocognitive disorders or gp120 neurotoxicity

  • Generate conditional knockin mouse models expressing S522A-CRMP2 (non-phosphorylatable)

• Cell-based models:

  • Manipulate CDK5 activity in primary neurons or neural progenitor cells

  • Examine effects of disease-relevant proteins (e.g., HIV gp120, Aβ peptides) on CRMP-2 phosphorylation

  • Study the impact of S522A-CRMP2 mutation on dendritic spine formation and neuronal morphology

Published research has demonstrated that "phosphorylated CRMP2 associates with damaged neurites and neurofibrillary tangles, and accumulates in neurons surrounding cortical amyloid plaques" in Alzheimer's disease brains .

How can DPYSL2 (Ab-522) antibody be used in conjunction with other techniques to study neuronal cytoskeleton dynamics?

To comprehensively study how CRMP-2 phosphorylation affects cytoskeletal dynamics:

• Combined immunocytochemistry approaches:

  • Co-stain for pSer522-CRMP2 along with tubulin, actin, and other cytoskeletal markers

  • Use super-resolution microscopy to examine co-localization at the nanoscale level

  • Perform live-cell imaging with fluorescently tagged CRMP-2 variants (WT vs. S522A)

• Biochemical interaction studies:

  • Use pull-down assays to compare tubulin binding affinity of phosphorylated versus non-phosphorylated CRMP-2

  • Conduct in vitro microtubule polymerization assays with purified components

  • Employ proximity ligation assays to detect CRMP-2/tubulin interactions in situ

• Advanced cellular techniques:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure cytoskeletal dynamics

  • Implement optogenetic control of CRMP-2 phosphorylation to study real-time effects

  • Utilize microfluidic chambers to examine axon growth and guidance in response to phosphorylation changes

Research indicates that "Non-phosphorylated DPYSL2 promotes axonal elongation and branching by binding to tubulin heterodimer whereas its phosphorylation by GSK3β, ROCK2 and Cdk5 lowers binding affinity of DPYSL2 to tubulin leading to growth cone collapse and arrest of axonal outgrowth" .

What is the functional significance of CRMP-2 phosphorylation at Ser522 in neuronal development?

CRMP-2 phosphorylation at Ser522 plays critical roles in neuronal development by:

• Regulating neurite outgrowth:

  • Non-phosphorylated CRMP-2 promotes neurite extension by stabilizing microtubules

  • Phosphorylation at Ser522 initiates a process that reduces CRMP-2's binding to tubulin

  • This leads to destabilization of the cytoskeleton and growth cone collapse

• Mediating semaphorin signaling:

  • Semaphorin 3A activates CDK5, leading to CRMP-2 phosphorylation at Ser522

  • This phosphorylation is necessary for semaphorin-induced growth cone collapse

  • It represents a key pathway in axon guidance during development

• Regulating dendritic spine development:

  • "Nonphosphorylated CRMP2 is expressed throughout the neuron, including the dendritic spines; phosphorylated CRMP2 is not expressed in the spines"

  • This creates "a continuous dynamic in which CRMP2 enters and fills the spines when it is activated/dephosphorylated and is absent from or leaves the spines when it becomes inactivated/phosphorylated"

The phosphorylation state of CRMP-2 essentially acts as a molecular switch between growth promotion and growth inhibition during neural development.

What is the relationship between CDK5-mediated phosphorylation of CRMP-2 at Ser522 and neurodegenerative conditions?

CDK5-mediated phosphorylation of CRMP-2 at Ser522 has been implicated in several neurodegenerative conditions:

• Alzheimer's disease:

  • Hyperphosphorylation of CRMP-2 is observed in AD brains

  • "Phosphorylated CRMP2 associates with damaged neurites and neurofibrillary tangles, and accumulates in neurons surrounding cortical amyloid plaques"

  • This suggests dysregulation of the normal phosphorylation/dephosphorylation balance

• HIV-associated neurocognitive disorders:

  • "Levels of total and phosphorylated (Ser522) CRMP2 were significantly increased in neurogenic sites of the hippocampus from HIVE patients"

  • Similar results were observed in a mouse model of HIV-gp120 neurotoxicity

  • This implicates CRMP-2 phosphorylation in HIV-mediated neurodegeneration

• Psychiatric disorders:

  • Abnormal CRMP-2 phosphorylation has been linked to schizophrenia

  • In bipolar disorder, "p-CRMP2:CRMP2 ratio was significantly elevated in LiR BPD patients compared with unaffected controls"

  • This suggests roles in structural neuronal abnormalities associated with psychiatric conditions

The disruption of normal CRMP-2 phosphorylation appears to be a common pathway in diverse neurological conditions, suggesting it may represent a potential therapeutic target.

Beyond CDK5, what other kinases and pathways regulate CRMP-2 phosphorylation and function?

CRMP-2 phosphorylation is regulated by multiple kinases and pathways:

• Primary kinases and their target sites:

  • CDK5: Phosphorylates Ser522 (priming site)

  • GSK3β: Phosphorylates Thr514, Thr518, and Thr509 (requires Ser522 priming)

  • ROCK: Phosphorylates Thr555

  • DYRK2: Can also phosphorylate Ser522

• Upstream signaling pathways:

  • Semaphorin 3A activates both CDK5 and GSK3β pathways

  • Neurotrophin signaling inhibits GSK3β, reducing CRMP-2 phosphorylation

  • Rho GTPase pathways activate ROCK, leading to CRMP-2 phosphorylation

  • Calcium signaling can indirectly modulate CRMP-2 phosphorylation

• Regulation by phosphatases:

  • Protein phosphatase 2A (PP2A) dephosphorylates CRMP-2

  • Inhibition of phosphatases leads to hyperphosphorylation

  • The balance between kinase and phosphatase activities determines the net phosphorylation state

• Additional regulatory mechanisms:

  • "The functions of DPYSL proteins are also regulated by other post-translational modifications including acylation, SUMOylation and O-GlcNAcylation"

  • "DPYSL2 phosphorylation at Serine 522 by Cdk5 promotes association between DPYSL2 and cytoplasmic loops of CaV2.2, leading to an increase of Ca2+"